Loading…
Tevogen Bio Holdings Inc. is projected to decline to $4.65 by 2027, a -8% move from its current price of $5.06. TVGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.70 | $5.06 | $5.46 | +0.06% |
| Jul 14 | $4.55 | $5.07 | $5.63 | +0.11% |
| Jul 15 | $4.45 | $5.07 | $5.77 | +0.17% |
| Jul 16 | $4.36 | $5.07 | $5.89 | +0.22% |
| Jul 17 | $4.29 | $5.07 | $6.00 | +0.28% |
| Jul 18 | $4.22 | $5.08 | $6.10 | +0.34% |
| Jul 19 | $4.16 | $5.08 | $6.20 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.16 | $5.08 | $6.20 | +0.39% |
| Week 2 | $3.85 | $5.10 | $6.76 | +0.79% |
| Week 3 | $3.63 | $5.12 | $7.23 | +1.18% |
| Week 4 | $3.45 | $5.14 | $7.65 | +1.58% |
| Week 5 | $3.31 | $5.16 | $8.05 | +1.98% |
| Week 6 | $3.18 | $5.18 | $8.44 | +2.38% |
| Week 7 | $3.07 | $5.20 | $8.81 | +2.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company that develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc.
and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Tevogen Bio Holdings Inc. trades under the symbol TVGN and operates in the healthcare sector as a clinical-stage immunotherapy developer. The stock is currently valued at $5.06 per share, with a market capitalization of $21.35M and a market rank of 4855.
The long-range forecast depicts a varied path from today toward higher levels in later years, with notable upside potential in select years. In 2032 and beyond, the forecast points to higher average levels than today, reflecting-candidate upside on a multi-year horizon.
A major floor 87.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 130.6% above — a clean break opens room to run.
A major ceiling 174.2% above — clearing it would confirm fresh momentum.
Key TVGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.45 | Sell | $5.48 | Sell |
| MA 10 | $5.77 | Sell | $6.12 | Sell |
| MA 20 | $7.84 | Sell | $7.11 | Sell |
| MA 50 | $8.25 | Sell | $8.00 | Sell |
| MA 100 | $8.05 | Sell | $10.11 | Sell |
| MA 200 | $15.91 | Sell | $18.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.30 | Neutral |
| Stoch RSI (14) | 5.73 | Buy |
| CCI (20) | -89.58 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.35 | Sell |
| ROC (12) | -46.79 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.10 | Sell |
| Awesome (5,34) | -3.04 | Sell |
| Ultimate (7,14,28) | 30.67 | Neutral |
| Momentum (10) | -4.48 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 5.20 | Sell |
| ADX (14) | 21.35 | Sell |
| ATR (14) | 0.55 | Info |
The 30-day technical picture is Bearish, with RSI14 at 30. The stock is trading below the 50-day and 200-day moving averages; SMA50 is $8.25 and SMA200 is $15.91. Immediate support stands at $5.06, while resistance is noted at $11.67. The 30-day price range spans from $3.08 to $8.31, highlighting recent volatility within a relatively tight near-term band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.29 | $5.06 | $7.39 | 0% | Neutral | |
| $3.38 | $4.65 | $6.93 | -8% | Neutral | |
| $2.57 | $3.76 | $5.97 | -26% | Bearish | |
| $2.75 | $4.24 | $7.07 | -16% | Bearish | |
| $2.68 | $4.33 | $7.52 | -14% | Neutral | |
| $3.36 | $5.68 | $10.21 | +12% | Neutral | |
| $3.62 | $6.38 | $11.82 | +26% | Bullish | |
| $3.05 | $5.61 | $10.68 | +11% | Neutral | |
| $3.06 | $5.84 | $11.41 | +15% | Neutral | |
| $2.74 | $5.44 | $10.86 | +7% | Neutral | |
| $3.49 | $7.75 | $17.01 | +53% | Bullish | |
| $5.71 | $12.70 | $29.20 | +151% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.29 | $5.06 | $6.05 | +0.00% |
| August 2026 | $4.26 | $5.16 | $6.50 | +1.91% |
| September 2026 | $4.33 | $5.32 | $6.86 | +3.26% |
| October 2026 | $4.14 | $5.14 | $6.74 | -3.41% |
| November 2026 | $4.13 | $5.18 | $6.89 | +0.79% |
| December 2026 | $4.33 | $5.49 | $7.39 | +5.87% |
Click any year to see its month-by-month TVGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tevogen Bio Holdings Inc.'s 2026 outlook centres on $5.06, within a $4.29 to $7.39 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TVGN could reach as high as $6.93, with a base case around $4.65 and support toward $3.38 — roughly -8% from $5.06. A consolidation phase looks the most probable path here.
Expect TVGN to range from $2.57 to $5.97 through 2028. The $3.76 average target implies a -26% move from current prices. That is -19% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The TVGN price prediction for 2029 points to an average of $4.24 (low $2.75, high $7.07) — a potential decline of -16% on today's $5.06. Expect choppier, lower action through this leg of the cycle.
In 2030, TVGN is projected to trade between $2.68 and $7.52, averaging $4.33 — a potential decline of -14% from today's $5.06. That is up +2% on the projected 2029 average. Price action looks broadly range-bound.
Tevogen Bio Holdings Inc.'s 2031 outlook centres on $5.68, within a $3.36 to $10.21 range. That is up +31% on the projected 2030 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, TVGN could reach as high as $11.82, with a base case around $6.38 and support toward $3.62 — roughly +26% from $5.06. Momentum favours further upside here.
Expect TVGN to range from $3.05 to $10.68 through 2033. The $5.61 average target implies a +11% move from current prices. That is -12% versus the projected 2032 average. A consolidation phase looks the most probable path here.
The TVGN price prediction for 2034 points to an average of $5.84 (low $3.06, high $11.41) — a potential gain of +15% on today's $5.06. Price action looks broadly range-bound.
In 2035, TVGN is projected to trade between $2.74 and $10.86, averaging $5.44 — a potential gain of +7% from today's $5.06. That is -7% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Tevogen Bio Holdings Inc.'s 2040 outlook centres on $7.75, within a $3.49 to $17.01 range. That is up +42% on the projected 2035 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2050, TVGN could reach as high as $29.20, with a base case around $12.70 and support toward $5.71 — roughly +151% from $5.06. Buyers look set to stay in control over this stretch.
Investing $1,000 in TVGN today (≈ 197.628458 TVGN) could be worth
$2,509.22
+$1,509.22 (+151%) by 2050 · US Dollar
Based on the average projected TVGN price of $12.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVGNwould be worth at today's price.
$1,000 invested in TVGN on Jul 10, 2025 (≈ 16.393443 TVGN) would be worth
$82.95
-$917.05 (-91.7%) today · 0.08× · US Dollar
Based on a TVGN entry price of $61 vs. today's $5.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.77 | $876.95 | -12.3% |
| 1 month ago | $10.6 | $477.36 | -52.3% |
| 3 months ago | $5.73 | $883.07 | -11.7% |
| 6 months ago | $16.25 | $311.38 | -68.9% |
| 1 year ago | $61 | $82.95 | -91.7% |
| All time (4.5y) ago | $496.85 | $10.18 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVGN forecast.
Our base-case forecast reaches $10.00 around 2050.
Implied market cap at $10.00: $42.19M
The year-by-year forecast shows a mixed near-term path and clearer upside later. In 2026 the avg is $5.06, with a min of $4.29 and a max of $7.40 and an ROI of 0. In 2027 the avg is $4.64, with a min of $3.37 and a max of $6.92 and an ROI of -8.3.
In 2028 the avg is $3.76, with a min of $2.56 and a max of $5.97 and an ROI of -25.8. In 2029 the avg is $4.25, with a min of $2.76 and a max of $7.09 and an ROI of -16. In 2030 the avg is $4.33, with a min of $2.67 and a max of $7.51 and an ROI of -14.5.
By 2031 the avg improves to $5.68 (ROI 12.3) and 2032 to $6.39 (ROI 26.2), with 2033 at $5.60 (ROI 10.6), 2034 at $5.85 (ROI 15.6), and 2035 at $5.44 (ROI 7.6). The forecast then shows 2040 with an avg of $7.76 (ROI 53.3) and 2050 with an avg of $12.71 (ROI 151.2), both labeled as bullish. These figures imply a trajectory of early volatility followed by meaningful longer-term upside, acknowledging that actual results may differ and risks remain.
Tap a question to reveal the answer.
2030 min $2.67, avg $4.33, max $7.51; ROI -14.5; sentiment Neutral.
The forecast shows neutral sentiment in the near term (2026-2030) with some negative ROI in 2027-2030, followed by positive momentum later (2031-2032 and beyond), including 2032 avg $6.39 and ROI 26.2, and 2050 avg $12.71 with ROI 151.2.
Yes. The forecast max values exceed $10 in several years: 2031 max $10.21, 2033 max $10.66, and 2034 max $11.42.
2032 min $3.62, avg $6.39, max $11.83; ROI 26.2; sentiment Bullish.
Current price is $5.06 and market cap is $21.35M.
Tevogen Bio Holdings Inc. Community Discussion
0Share your Tevogen Bio Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.